Uniogen develops point-of-care diagnostic testing kits utilizing glycovariant immunoassay technology and Upcon® labeling, enabling high sensitivity and specificity in detecting infectious and cancerous diseases. Their solutions address the need for rapid and reliable diagnostics in clinical settings, facilitating early detection and improved patient outcomes.
Funding
$3.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Conventional immunoassays for cancer and infectious diseases often lack the sensitivity and specificity needed for early and accurate diagnosis, leading to delayed treatment and poorer patient outcomes. Existing diagnostic methods may also suffer from limitations such as photobleaching, self-quenching, and autofluorescence, hindering reliable detection, especially in complex biological samples.
Solution
Uniogen develops advanced diagnostic solutions utilizing glycovariant immunoassay technology and Upcon® labeling to enhance the detection of infectious and cancerous diseases. The core technology uses nanoparticles coated with carbohydrate group-specific binders at a high density, improving sensitivity and specificity compared to traditional assays. Upcon® labeling employs photostable upconverting nanoparticles, enabling measurements without photobleaching, self-quenching, or autofluorescence, even in tissue and whole blood. Uniogen provides a range of products, including ready-to-use reagents, components, and custom assay development services for high-quality IVD immunoassays and antibody tests. Additionally, the company manufactures modular microplate readers with built-in dispensers and flexible software compatible with various assay types and plate formats.
Target Audience
Uniogen's primary customers include clinical laboratories, research institutions, and healthcare providers focused on early disease detection and improved diagnostic accuracy.
Features
- Glycovariant immunoassay technology for improved sensitivity and specificity in detecting cancer biomarkers
- Upcon® labeling technology utilizing photostable upconverting nanoparticles for enhanced detection in complex samples
- GenomEra® CDX system for rapid and cost-efficient molecular diagnostics with high assay reliability
- Modular microplate readers with built-in dispensers and versatile assay compatibility
- Custom assay development services, including kit manufacturing, plate production, and biomolecule conjugation
- Ready-to-use reagents and components for IVD immunoassays and antibody tests
- Multiplexed detection capabilities for simultaneous analysis of multiple targets